HopeStage
Back to all studies
CompletedNCT01479829

Escitalopram With Celecoxib or Placebo for Depression Related to Bipolarity

About this title

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

Read the official source — NCT01479829
Medication studyAges 21–65United States
The study in practice

Understand this study

Who was this study for?

This study was for people with bipolarity. Listed age limits: 21 years to 65 years. Other eligibility criteria applied.

Listed locations
MaywoodSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: March 23, 2011
Recruitment status
Completed
Enrollment listed in the registry
100
Sponsor
Loyola University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 21 Years to 65 Years
Official registry ID
NCT01479829
Official title
Show the full official title

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression: Role of Inflammation and Kynurenine Pathway Biomarkers

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Maywood

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Loyola University, a university.

Did this study involve medication?

Yes. The study involved medication, including Escitalopram, Celecoxib and Placebo.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 21 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies